ALK`s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan
(WorldNews Denmark)

Copenhagen, 2017-03-24 08:00 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii Pharmaceutical Co., Ltd., has submitted an application to the Japanese Ministry of Health, Labour and Welfare, seeking to expand the use of ALK`s house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURETM to include paediatric allergic rhinitis patients. MITICURETM, which is sold by ALK as ACARIZAX in Europe, has been approved in Japan since 2015 for adults and adolescents aged 12-64 who suffer from house dust mite-induced allergic rhinitis. The product is included on the Japanese National Health...